Indian Pharmas In Trend To Focus On Targeted Drugs
This article was originally published in PharmAsia News
Indian pharmaceutical companies are joining what appears to be a global trend of pharmas to shift their emphases to specialized or targeted drugs rather than relying on blockbusters. Dr. Reddy's Laboratories, Wockhardt and Lupin Pharmaceuticals are, as are several multinational drug makers, increasingly focused on cancer molecules, monoclonal antibodies and vaccines. Part of the change has come about because of moves by generics makers into supplying medicines used in primary care. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.